Mosla dianthera Decreases Immediate-Type Allergic Reaction and Tumor Necrosis Factor-α Production

Sang-Hyun Kim, a,# Hoon Jeon, b,# Soyoung Lee, a Hee-Young Son, a Seung-Bin Park, a Mi-Sun Kim, a Eun-Ju Choi, a Jong-Pil Lim, b Jae-Soon Eun, b Jeong-Suk Park, c and Tae-Yong Shin b,*

aCell & Matrix Research Institute, Department of Pharmacology, School of Medicine, Kyungpook National University, 101 Dongindong 2 Ga, Jang-gu, Daegu 700–422, Republic of Korea, bCollege of Pharmacy, Woosuk University, 490 Hujeong-ri, Samrye-eup, Wanju-gun, Jeonbuk 565–701, Republic of Korea and cDepartment of Oriental Alternative Medicine, Nambu University, 864–1 Wolgye-dong, Gwangsan-gu, Gwangju 506–706, Republic of Korea

(Received January 7, 2008; Accepted May 20, 2008)

Immediate-type hypersensitivity is involved in many allergic diseases such as asthma, allergic rhinitis, and sinusitis. The discovery of drugs for the treatment of allergic disease is an important subject in human health. Stimulation of mast cells releases inflammatory mediators, such as histamine, and proinflammatory cytokines with immune regulatory properties. We investigated the effect of the aqueous extract of Mosla dianthera (M. dianthera) (Maxim) (AEMD) on the immediate-type allergic reaction and studied its possible mechanisms of action using the model of mast cell-mediated allergic reaction. AEMD dose dependently inhibited compound 48/80-induced systemic allergic reaction and serum histamine release in mice. AEMD attenuated immunoglobulin E (IgE)-mediated skin allergic reaction and histamine release from mast cells. In addition, AEMD decreased the gene expression and production of tumor necrosis factor (TNF)-α in phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187-stimulated human mast cells. Our findings provide evidence that AEMD inhibits the mast cell-derived allergic reaction and that TNF-α is involved in these effects. These findings indicate that AEMD could be a candidate as an antiallergic agent.

Key words —— Mosla dianthera, allergic reaction, mast cell, histamine, tumor necrosis factor-α

INTRODUCTION

Mast cells, which are constituents of virtually all organs and tissues, are important mediators of allergic responses such as allergic inflammation and hypersensitivity. The immediate-type allergic reaction (hypersensitivity) is an acute systemic allergic reaction mediated by histamine released in response to the antigen cross-linking of immunoglobulin E (IgE) bound to FcεRI on mast cells. After activation via FcεRI, mast cells start the process of degranulation which results in the release of mediators, such as products of arachidonic acid metabolism and an array of inflammatory cytokines.1–3) Among the inflammatory substances released from mast cells, histamine remains the best-characterized and most potent vasoactive mediator implicated in the acute phase of immediate hypersensitivity.4, 5)

Anti-dinitrophenyl (DNP) IgE antibody and antigen have been established to induce passive cutaneous anaphylaxis (PCA) reactions as a typical in vivo model of hypersensitivity. Mast cell degranulation can also be elicited by nonimmunologic stimulators such as neuropeptides, basic compounds, complement components, and certain drugs.6) Compound 48/80 and polymers of basic amino acids, such as substance P, are some of the most potent stimulators of mast cells. Thus an appropriate amount of compound 48/80 has been used as a direct and convenient reagent to study the mechanism of anaphylactic allergic reaction.

The signaling pathway leading to degranulation of mast cells after engagement of the FcεRI receptor has been extensively characterized.6) Activation of mast cells leads to phosphorylation of tyrosine kinase, mobilization of internal calcium, and release

#These authors contributed equally to this work.

*To whom correspondence should be addressed: College of Pharmacy, Woosuk University, 490 Hujeong-ri, Samrye-eup, Wanju-gun, Jeonbuk 565–701, Republic of Korea. Tel.: +82-63-290-1572; Fax: +82-63-290-1567; E-mail: tyshin@woosuk.ac.kr
of inflammatory cytokines. Although mast cells also store small amounts of cytokines in their granules, these cells dramatically increase the production of tumor necrosis factor (TNF)-α and other cytokines after their surface FcεRI is cross-linked with specific antigen.\(^7,8\)

Anal therapy is a drug delivery system through the anus and is utilized in patients who have difficulty with oral administration. Absorbing a drug in the rectum avoids the first-pass effect in the liver and allows it to circulate directly in the whole body.\(^9,10\) Thus anal therapy is expected to have a better effect than oral therapy due to the increased absorption rate and potent medical action.

*Mosla dianthera* (*M. dianthera*) Maxim has been used for centuries as traditional Oriental medicine. This crude drug contains volatile flavor compounds and aroma-active compounds, mainly carvone, limonene, and beta-caryophyllene, and linalool, 3-hexenol, and myrcene, respectively.\(^11\) It is native to Korea, China, Japan, and Vietnam and an annual aromatic plant of the labiatae family. It has been used as a medicinal plant to treat colds, headaches, and intestinal and skin diseases.\(^12,13\) In this study, we investigated the antiallergic effects of the aqueous extract of *M. dianthera* (AEMD) and attempted to understand the mechanism of its effect.

**MATERIALS AND METHODS**

**Animals** —— The original stock of male Imprinting Control Region (ICR) mice and male Sprague-Dawley rats were purchased from the Dae-Han Experimental Animal Center (Daejeon, Korea). The animals were maintained in the College of Pharmacy, Woosuk University. The animals were housed 5–10 per cage in a laminar air flow room (conventional conditions), maintained at a temperature of 22 ± 2°C, with a relative humidity of 55 ± 5% throughout the study. The care and treatment of the mice were in accordance with the guidelines established by the Public Health Service Policy on the Humane Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.

**Reagents and Cell Culture** —— Compound 48/80, anti-DNP IgE, DNP-human serum albumin (HSA), α-minimal essential medium (α-MEM), α-phthalaldehyde, phorbol 12-myristate 13-acetate (PMA), and calcium ionophore A23187 were purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.). The human mast cell line (HMC-1) was grown in Iscove’s media (Life Technologies, Grand Island, NY, U.S.A.) supplemented with 10% Fetal bovine serum (FBS) and glutamine 2 mM at 37°C in 5% CO₂.

**Preparation of AEMD** —— The plant of *M. dianthera* was collected in Soonchnag, South Korea, on the August 13, 2000. A voucher specimen (WSP-00-42) was deposited in the Herbarium of the College of Pharmacy, Woosuk University. *M. dianthera* was ground (1000 rpm, 30 sec) at room temperature using a Micro Hammer Cutter Mill (Culatti Co., Zurich, Switzerland). The particle size was 0.5–2 mm after grinding. The plant sample (60 g) was extracted twice with purified water (500 ml) at 70°C for 5 hr in a water bath. The extract was filtered through Whatman No.1 filter paper and the filtrate was lyophilized using a 0.45 µm syringe filter. The yield of dried extract from starting crude materials was about 7.5%. The dried extract was dissolved in saline or Tyrode buffer A (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10 mM, NaCl 130 mM, KCl 5 mM, CaCl₂ 1.4 mM, MgCl₂ 1 mM, glucose 5.6 mM, 0.1% bovine serum albumin) before use.

**Compound 48/80-induced Systemic Reaction** —— Mice were given an intraperitoneal injection of 8 mg/kg body weight (BW) of the mast cell degranulator compound 48/80. AEMD was dissolved in saline and anally administered 1 hr before the injection of compound 48/80 (n = 10/group). Mortality was monitored for 1 hr after induction of anaphylactic shock. After the mortality test, blood was obtained from the heart of each mouse to measure the serum histamine content.

**PCA Reaction** —— An IgE-dependent cutaneous reaction was examined as previously described.\(^14\) The PCA reaction was generated by sensitizing skin with an intradermal injection of anti-DNP IgE followed 48 hr later with an injection of DNP-HSA into the mouse tail vein. The mice were injected intradermally with 0.5 µg of anti-DNP IgE. After 48 hr, each mouse was received an injection of 1 µg of DNP-HSA containing 4% Evans blue (1 : 4) via the tail vein. Thirty minutes after the challenge, the mice were killed and the dorsal skin was removed for measurement of the pigmented area. The amount of dye was determined colorimetrically after extraction with 1 ml of Potassium hydroxide (KOH) 1 M and 9 ml of a mixture of acetone and phosphoric acid (5 : 13).\(^14\) The intensity of ab-
sorbance was measured at 620 nm in a spectrophotometer (UV-1201, Shimadzu, Kyoto, Japan).

**Preparation of Serum and Histamine Determination** —— The blood was centrifuged at 400 g for 10 min. The serum was withdrawn and the histamine content was measured using the o-phthalaldehyde spectrofluorometric procedure. The fluorescence intensity was measured at the emission wavelength of 438 nm and excitation wavelength of 353 nm using a spectrofluorometer (RF-5301 PC, Shimadzu).

**Preparation of Rat Peritoneal Mast Cells (RPMC)** —— RPMC were isolated as previously described. In brief, rats were anesthetized by ether and injected with 20 ml of Tyrode buffer B (NaCl 137 mM, glucose 5.6 mM, NaHCO₃ 12 mM, KCl 2.7 mM, NaH₂PO₄ 0.3 mM, and 0.1% gelatin) into the peritoneal cavity, and the abdomen was gently massaged for about 90 sec. The peritoneal cavity was carefully opened, and the fluid containing peritoneal cells was aspirated with a Pasteur pipette. The peritoneal cells were sedimented at 150 g for 10 min at room temperature and resuspended in Tyrode buffer B. Mast cells were separated from the major components of rat peritoneal cells, i.e., macrophages and small lymphocytes. In brief, peritoneal cells were suspended in 1 ml of Tyrode buffer B, layered on 2 ml of metrizamide (22.5 w/v%), and centrifuged at room temperature for 15 min at 400 g. The cells remaining at the buffer-metrizamide interface were aspirated and discarded; the cells in the pellet were washed and resuspended in 1 ml of Tyrode buffer A. Mast cell preparations were about 95% pure as assessed by toluidine blue staining.

**Inhibition of Histamine Release** —— RPMC suspensions (2 × 10⁵ cells/ml) were sensitized with anti-DNP IgE (10 µg/ml) for 16 hr. The cells were preincubated with AEMD (0.01 to 1 mg/ml) at 37°C for 10 min prior to the challenge with DNP-HSA (1 µg/ml) for 10 min. The cells were separated from the released histamine by centrifugation at 400 g for 5 min at 4°C.

**Reverse-transcriptase Polymerase Chain Reaction (RT-PCR)** —— The total cellular RNA was isolated from the cells (1 × 10⁶/well in a 24-well plate) after stimulation with PMA (20 nM) and A23187 (1 µM) with or without AEMD for 2 hr using a TRI reagent (Molecular Research Center, Cincinnati, OH, U.S.A.) according to the manufacturer’s protocol. The first-strand complementary DNA (cDNA) was synthesized using the Superscript II reverse transcriptase (Life Technologies). RT-PCR was used to analyze the expression of mRNA for TNF-α and β-actin (internal control). The conditions for the reverse transcription and PCR steps were similar to those previously described. The primer sets were chosen with the Primer 3 program (Whithead Institute, Cambridge, MA, U.S.A.). The cycle number was optimized to ensure product accumulation in the exponential range. The amplified products were separated by electrophoresis on 2% agarose gel containing ethidium bromide, documented using a Kodak DC 290 digital camera, and digitized with UN-SCAN-IT software (Silk Scientific, Orem, UT, U.S.A.). The band intensity was normalized to that of β-actin in the same sample.

**Western Blot Analysis** —— Cell extracts were prepared using the detergent lysis procedure. Samples of protein (50 µg) were electrophoresed using 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), as described elsewhere, and then transferred to a nitrocellulose membrane. The amount of TNF-α was determined using anti-TNF-α antibody (R&D Systems Inc., Minneapolis, MN, U.S.A.). Immunodetection was performed using an enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ, U.S.A.).

**Statistical Analysis** —— Statistical analyses were performed using SAS statistical software (SAS Institute, Cary, NC, U.S.A.). Treatment effects were analyzed using one-way analysis of variance, followed by Duncan’s multiple-range test. A value of p < 0.05 was used to indicate statistically significant differences.

**RESULTS**

**AEMD Inhibits Compound 48/80-induced Systemic Allergic Reaction**

To determine the effect of AEMD on allergic reaction, an *in vivo* model of systemic reaction was used. Compound 48/80 (8 mg/kg BW) was used as a model for the induction of a systemic fatal allergic reaction. After the intraperitoneal injection of compound 48/80, the mice were monitored for 1 hr, after which the mortality rate was determined. As shown in Table 1, injection of compound 48/80 in mice induced fatal shock in 100% of animals. When AEMD was anally administered at concentrations ranging from 0.01 to 1 mg/g BW for 1 hr, the mor-
Table 1. Effects of AEMD on Compound 48/80-Induced Systemic Anaphylaxis

<table>
<thead>
<tr>
<th>AEMD treatment (mg/g BW)</th>
<th>Compound 48/80 (8 mg/kg BW)</th>
<th>Mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (saline)</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>0.01</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>0.05</td>
<td>+</td>
<td>80</td>
</tr>
<tr>
<td>0.1</td>
<td>+</td>
<td>40</td>
</tr>
<tr>
<td>0.5</td>
<td>+</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>−</td>
<td>0</td>
</tr>
</tbody>
</table>

Groups of mice (n = 10/group) were anally pretreated with 200µl of saline or AEMD at various doses 1 hr before the intraperitoneal injection of compound 48/80. Mortality (%) within 1 hr following compound 48/80 injection is represented as the number of dead mice x 100/total number of experimental mice. BW, body weight.

Table 2. Time-Dependent Effects of AEMD on Compound 48/80-Induced Systemic Anaphylaxis

<table>
<thead>
<tr>
<th>AEMD treatment (mg/g BW)</th>
<th>Compound 48/80 (8 mg/kg BW)</th>
<th>Time (min)</th>
<th>Mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (saline)</td>
<td>+</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>+</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>10</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>20</td>
<td>100</td>
</tr>
</tbody>
</table>

Mice (n = 10/group) were anally pretreated with 200µl of saline or AEMD. AEMD (1 mg/g) was given 5, 10, and 20 min after the intraperitoneal injection of compound 48/80. Mortality (%) within 1 hr following compound 48/80 injection is represented as the number of dead mice x 100/total number of experimental mice. BW, body weight.

Mortality with compound 48/80 was dose dependently reduced. In addition, the mortality of mice administered AEMD anally (1 mg/g) 5, 10, and 20 min after compound 48/80 injection increased time dependently (Table 2).

AEMD Decreases Compound 48/80-induced Serum Histamine Release

The effect of AEMD on compound 48/80-induced serum histamine release was investigated. AEMD was given at concentrations ranging from 0.01 to 1 mg/g BW 1 hr before (n = 10/group) compound 48/80 injection (Fig. 1). The inhibition rate due to treatment with AEMD was significant at doses of 0.1 and 1 mg/g.

AEMD Inhibits the PCA Reaction

PCA is one of the most important in vivo models of local allergic reaction.9) As described in the experimental procedures, local extravasation was induced by a local injection of anti-DNP IgE, followed by an intravenous antigenic challenge.

AEMD dose dependently inhibited the PCA reaction (Fig. 2).

AEMD Reduces IgE-mediated Histamine Release from RPMCs

The inhibitory effects of AEMD on IgE-mediated histamine release from RPMCs are shown in Fig. 3. AEMD dose dependently inhibited anti-DNP IgE-mediated histamine release at concentrations of 0.1 and 1 mg/ml.

AEMD Inhibits Gene Expression and Production of TNF-α from HMC-1 Cells

TNF-α is one of the most important proinflam-
Fig. 3. Effects of AEMD on the IgE-Mediated Histamine Release from RPMCs

Cells were preincubated with AEMD 10 min prior to incubation with DNP-HSA. Each bar represents the mean ± SEM of three independent experiments. *Significant difference at p < 0.05.

mastocytic cytokines. Therefore we examined the effects of AEMD on the gene expression and production of TNF-α using RT-PCR and Western blotting, respectively. HMC-1 are useful for studying the synthesis of mediators and cytokine activation pathways. As shown in Fig. 4A, the gene expression of TNF-α was increased after stimulation with PMA and A23187. Pretreatment with AEMD inhibited PMA- and A23187-induced production of TNF-α mRNA. Pretreatment with AEMD also decreased PMA- and A23187-induced production of TNF-α protein (Fig. 4B). The concentration of AEMD used in the experiment did not interfere with the viability of cells as assessed in the trypan blue dye-exclusion test.

DISCUSSION

Mast cell-mediated hypersensitivity is a life-threatening syndrome induced by the sudden systemic release of inflammatory mediators, such as histamine, heparin, lipid derived mediators, and various cytokines from mast cells. Mast cells are located throughout the human body and upon allergen exposure, they are stimulated via the IgE receptor.

The results of this study demonstrated that AEMD has the antiallergic properties. Pretreatment with AEMD profoundly inhibited the compound 48/80-induced systemic reaction and IgE-mediated local allergic reaction. AEMD inhibited IgE-mediated histamine release from RPMCs. These results indicate that mast cell-mediated hypersensitivity is inhibited by AEMD. It is known that stimulation of mast cells with compound 48/80 or IgE initiates the activation of a signal transduction pathway that leads to histamine release. Several recent studies have shown that compound 48/80 and other polybasic compounds are able, apparently directly, to activate G-proteins. It was reported that compound 48/80 increases the permeability of the lipid bilayer membrane by causing a perturbation of the membrane. This result indicates that the increase in membrane permeability may be an essential trigger for the release of the
mediator from mast cells. In this sense, antiallergic agents with a membrane stabilizing action may be desirable. AEMD may act on the lipid bilayer membrane, thus preventing the perturbation induced by compound 48/80.

The PCA is one of the most important in vivo models of anaphylaxis in local allergic reactions. The mice administered AEMD were protected from IgE-mediated PCA. This finding suggests that AEMD might be useful in the treatment of allergic skin reactions.

Mast cell-derived cytokines, especially TNF-α, have critical biological activity in allergic reactions. It has been reported that mast cells are a principal source of TNF-α in the human dermis, and degranulation of mast cells in the dermal endothelium is abrogated by the anti-TNF-α antibody. This report may indicate that a decrease in TNF-α is a one of the key indicators of reduced allergic symptoms. The HMC-1 cell line is useful for studying cytokine activation pathways. AEMD inhibited the production of TNF-α in PMA- and A23187-stimulated HMC-1 cells. This result may suggest that one possible pathway of the antiallergic effects of AEMD results from the reduction of TNF-α release from mast cells. The effect of AEMD on TNF-α production by mast cells in vivo and the contribution of mast cells as a source of TNF-α during allergic reactions are important areas for future studies. The results obtained in the present study show that AEMD contributes to the prevention or treatment of mast cell-mediated allergic reaction.

Acknowledgements This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Center for Healthcare Technology Development), by the KOSEF Research Universities Program/Center for Healthcare Technology Development), by the KOSEF, Basic Research Promotion Fund (KRF-2006-003-E00427).

REFERENCES


